Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY-341495
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Central (experimental; Intracerebroventricular)
01
Overview
LY-341495 is a potent, selective, and brain-penetrant research compound developed by Eli Lilly, primarily used as an orthosteric antagonist for group II metabotropic glutamate receptors (mGluR2 and mGluR3). Its antagonism at mGluR2/3 is highly specific, with Ki/IC50 values in the low nanomolar range. LY-341495 is frequently used in neuroscience research to investigate the function and therapeutic potential of group II mGluRs, particularly for psychiatric and neurological disorders, due to its rapid and robust antidepressant-like effects in animal models, modulation of synaptic plasticity, and interaction with molecular pathways such as mTORC1 and AMPA receptor signaling[1][2][4][5][10].
- Other names
- (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl)propanoic acid
02
Targets
GRM3 (mGluR3)GRM8 (mGluR8)GRM2 (mGluR2)
Beyond the preview
Go deeper on LY-341495.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY-341495.